SCI reúne recursos sobre inmunidad y SARS-CoV-2

49. Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic? Med Hypotheses. 2020 Apr 6:109707; doi: 10.1016/j.mehy.2020.109707
48. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution. Mol Diagn Ther. 2020 Apr 4:1–12; doi: 10.1007/s40291-020-00460-z.
47. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 6; doi: 10.1016/j.immuni.2020.03.007.
46. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 Apr 7:1–3; doi: 10.1038/s41423-020-0424-9.
45. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020 Apr 6:1; doi: 10.1038/s41577-020-0305-6.
44. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020 Apr 6:1; doi: 10.1038/s41577-020-0304-7.
43. Dysregulation of lung myeloid cells in COVID-19. Nat Rev Immunol. 2020 Apr 6:1; doi: 10.1038/s41577-020-0303-8.

42. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020 Mar 3; 1–4.
41. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020 Mar 3; 1–6.
40. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020 Mar 2; doi: 10.15698/cst2020.04.216.
39. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020 May;177:104759.
38. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury. Natl Sci Rev. 2020 Mar 9; nwaa037.
37. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 2020 Mar 4:1–3; doi: 10.1038/s41423-020-0385-z.
36. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12:ciaa248; doi: 10.1093/cid/ciaa248.
35. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718–1723.
34. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9(1):558–570.
33. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1;11(7):995–998.
32. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020 Mar 13; doi: 10.1016/S2213-2600(20)30119-3.
31. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020 Mar 13:nwaa041; doi: 10.1093/nsr/nwaa041.
30. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020 Mar 17:1–3; doi: 10.1038/s41423-020-0401-3.
29. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9(1):601–604.
28. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI J. 2020;19:410–417.
27. Profile of Specific Antibodies to SARS-CoV-2: The First Report. J Infect. 2020 Mar 21; doi: 10.1016/j.jinf.2020.03.012.
26. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2. Med Hypotheses. 2020 Jul;140:109686.
25. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System. Engineering (Beijing). 2020 Mar 20; doi: 10.1016/j.eng.2020.03.006.
24. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020 Mar 20; doi: 10.1016/j.healun.2020.03.012.
23. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020 Mar 19; doi: 10.1016/j.bbrc.2020.03.047.
22. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020 Mar 19:1–3; doi: 10.1038/s41423-020-0402-2.
21. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 Mar 19:1–8. doi: 10.1038/s41423-020-0400-4.
20. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020 Mar 25:116803; doi: 10.1016/j.jns.2020.116803.
19. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020 Mar 25:1–3; doi: 10.1038/s41575-020-0294-8.
18. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 Mar 23:1–4; doi: 10.1038/s41418-020-0530-3.
17. Host receptors: the key to establishing cells with broad viral tropism for vaccine production. Crit Rev Microbiol. 2020;0(0):1–22; doi: 10.1080/1040841X.2020.1735992.
16. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res. 2020;21:74.
15. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clin Immunol. 2020 Mar 25:108393; doi: 10.1016/j.clim.2020.108393.